Zoetis Inc. (LON:0M3Q)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 48.15B |
| Revenue (ttm) | 6.85B |
| Net Income (ttm) | 1.91B |
| Shares Out | n/a |
| EPS (ttm) | 4.25 |
| PE Ratio | 25.26 |
| Forward PE | 22.34 |
| Dividend | 1.49 (1.01%) |
| Ex-Dividend Date | Jul 18, 2025 |
| Volume | 1,750 |
| Average Volume | 2,757 |
| Open | 143.00 |
| Previous Close | 143.20 |
| Day's Range | 142.54 - 146.93 |
| 52-Week Range | 139.50 - 196.07 |
| Beta | 0.90 |
| RSI | 48.03 |
| Earnings Date | Nov 4, 2025 |
About Zoetis
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph... [Read more]
Financial Performance
In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.
Financial numbers in USD Financial StatementsNews
Zoetis: Much Bark, Little Bite - The Stock Remains Pricey
Zoetis Inc. is a global animal health leader with strong fundamentals and a robust innovation pipeline. Click here to read why ZTS stock is a Sell.
Top 15 High-Growth Dividend Stocks For October 2025
The Top 15 High-Growth Dividend Stock list for October 2025 targets a 12% long-term return, despite underperforming SPY and VIG in September. These 15 stocks offer a 1.4% average yield and have grown ...
Zoetis (ZTS) Gains FDA Nod for Innovative Livestock Parasite Treatment
Zoetis (ZTS) Gains FDA Nod for Innovative Livestock Parasite Treatment
Zoetis granted conditional approval of Dectomax-CA1 for parasitic infection in cattle
FDA conditionally approves Dectomax-CA1 to treat New World screwworm in cattle. Read more here.
Zoetis Receives Conditional Approval for Dectomax®-CA1 Injectable for the Prevention and Treatment of New World Screwworm Myiasis in Cattle
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced that Dectomax®-CA1 Injectable is the first and only parasite control product to receive conditional approval from ...
Zoetis (ZTS) Gains Conditional FDA Approval for Cattle Treatment
Zoetis (ZTS) Gains Conditional FDA Approval for Cattle Treatment
ZTS Quantitative Stock Analysis - Warren Buffett
Below is Validea's guru fundamental report for ZOETIS INC (ZTS). Of the 22 guru strategies we follow, ZTS rates highest using our Patient Investor model based on the published strategy of Warren Buffe...
Zoetis (ZTS) Surpasses Market Returns: Some Facts Worth Knowing
Zoetis (ZTS) concluded the recent trading session at $143.5, signifying a +1.68% move from its prior day's close.
Pet Pain For Investor Gain
ZTS is fundamentally a companion animal company, with the segment driving 68% of 2024 revenue and projected to reach 71% by 2030, fueled by aging pet demographics in the US. OA pain franchise, Librela...
How Do Investors Really Feel About Zoetis?
Zoetis's (NYSE: ZTS) short interest as a percent of float has risen 17.45% since its last report. According to exchange reported data, there are now 7.76 million shares sold short , which is 1.75% of...
Zoetis to Host Webcast and Conference Call on Third Quarter 2025 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, November 4, 2025. Chief Executive Officer Kristin...
Warren Buffett Detailed Fundamental Analysis - ZTS
Below is Validea's guru fundamental report for ZOETIS INC (ZTS). Of the 22 guru strategies we follow, ZTS rates highest using our Patient Investor model based on the published strategy of Warren Buffe...
ZTS November 21st Options Begin Trading
Investors in Zoetis Inc (Symbol: ZTS) saw new options become available today, for the November 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZTS options ...
Noteworthy Wednesday Option Activity: NVDA, COIN, ZTS
Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in NVIDIA Corp (Symbol: NVDA), where a total of 1.8 million contracts have traded so far, represent...
Zoetis (ZTS) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Zoetis (ZTS) stood at $146.25, denoting a -1.32% move from the preceding trading day.
January 2028 Options Now Available For Zoetis (ZTS)
Investors in Zoetis Inc (Symbol: ZTS) saw new options begin trading today, for the January 2028 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the tim...
Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain
ZTS secures CVMP's positive opinion recommending the approval of Portela, a long-acting OA pain therapy for cats, with final decision expected in late 2025.
Zoetis (ZTS) Awaits EU Approval for Innovative Cat Osteoarthritis Therapy
Zoetis (ZTS) Awaits EU Approval for Innovative Cat Osteoarthritis Therapy
Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--If approved, Zoetis' Portela will be the first long-acting anti-NGF mAb therapy for cats and is designed to provide 3 months of OA pain relief...
Argus Research Reiterates Buy Rating for ZTS with Price Target Unchanged | ZTS Stock News
Argus Research Reiterates Buy Rating for ZTS with Price Target Unchanged | ZTS Stock News
Zoetis Inc. (ZTS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Top 50 High-Quality Dividend Stocks For September 2025
I track a universe of 50 high-quality dividend growth stocks to identify attractive investment opportunities based on valuation and future return potential. My custom valuation model highlights 23 sto...
Phibro Animal Health: Zoetis Growth, Valuation Still Attractive
Zoetis: A Solid Dividend Growth Investment For The Long Haul
Zoetis leads in animal health with strong growth, innovation, and safe, fast-growing dividends—now trading near fair value. Learn why ZTS stock is a buy.